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Summary A flow cytometric technique has been established for accurately quantitating the cell surface
density of MHC antigens and the percentage of cells expressing MHC antigens in 38 colorectal tumours.
Thirty-four percent of tumours were partially or completely negative for HLA-ABC antigen expression.
Although the quantity of HLA-ABC antigens varied widely, there was no correlation between the density of
HLA-ABC antigens, or the percentage of cells expressing these antigens and clinicopathological stage. Fifty
percent of the colorectal tumours expressed HLA-DR with varying antigen densities. All of the poorly
differentiated tumours expressed HLA-DR but there was no correlation between expression of HLA-DR and
clinicopathological stage.
The aneuploid tumours expressed more HLA-ABC and HLA-DR antigens on a higher percentage of cells
than the diploid tumours. Abnormal expression of the tumour associated antigens CEA, Y haptenic blood
group and 791T p72 also correlated with expression of HLA-ABC and HLA-DR antigens on colorectal
tumours. The majority of early derived in vitro dividing cells failed to express both HLA-ABC and HLA-DR
antigens although they expressed high levels of tumour associated antigens. If there is a correlation between in
vitro and in vivo growth perhaps tumours are maintained and seeded by MHC antigen negative cells.
Malignant transformation of human cells may be associated
with changes in the expression of histocompatibility antigens
and the appearance of antigenic structures undetectable in
their normal counterparts. Lysis of neoplastic cells by cyto-
toxic T-lymphocytes depends upon the expression of class I
antigens in association with tumour antigens (Zinkernagel &
Doherty, 1979) whereas MHC class II molecules are required
for the presentation of tumour associated antigens to helper
T-cells (Benacerraf, 1981; Lonai et al., 1981). However, there
was no correlation between the expression of MHC antigens
and the extent and type of mononuclear tumour infiltrate
(Csiba et al., 1984; Whitwell et al., 1984). Furthermore,
Rognum et al., 1983 demonstrated that homogenous
expression of CEA and HLA-DR in colorectal tumours was
clearly associated with increasing tumour dissemination as
measured by Dukes' staging (Dukes, 1932).
Experiments with murine models have illustrated the
importance of MHC antigen expression in the immunology
of the tumour-host relationship (reviewed by Robins, 1986).
For example, several homozygous and heterozygous tumours
expressing cnly one H-2 antigen can be transfected with the
missing gene and express the relevant H-2 molecule(s) (Hui
et al., 1984; Wallich et al., 1985). This led to tumour
rejection in some cases and to abrogation of metastases in
others. In other models, H-2 deficient variants may be
selectively rejected (Karre et al., 1986). It is therefore con-
ceivable that the level of MHC antigen expression may be an
important factor in determining the growth and metastatic
properties of certain human tumours, although high levels of
expression may not necessarily be associated with more
effective recognition.
A rapid and accurate screen for quantitating MHC
antigen expression on individual tumour cells has therefore
been developed. The level of HLA-ABC and HLA-DR
antigen was assessed on a series of colorectal tumours in
relation to histological grade, clinicopathological stage,
expression of tumour associated antigens, DNA ploidy and
early in vitro growth.
Materials and methods
Tumour cells
Tumour cell suspension was prepared from tissue within 18 h
of removal. No loss in cell viability was observed in this time
period. Tissue was finely minced and disaggregated in 0.05%
collagenase (Boehringer, Mannheim, West Germany) as
previously described (Durrant et al., 1986a).
Monoclonal antibodies
Antibodies to MHC antigens HLA-ABC was detected by
monoclonal antibody W6/32 (Seralab, UK) which recognises
a determinant co-expressed on MHC class I heavy and light
chain (Barnstable et al., 1978). HLA-DR was detected by
RF-B-HLA-DR (Seralab, UK) which recognised a
monomorphic determinant on HLA-DR molecules (Bodger
et al., 1983).
Antibodies to tumour associated antigens A panel of 3
murine monoclonal antibodies reactive with tumour
associated antigens was used in this study. 79IT/36 antibody
recognises a glycoprotein of mol. wt. 72,000 (79IT p72)
which is found in a wide variety of tumours (Embleton et
al., 1981; Price et al., 1983) C14 antibody recognises a
difucosylated type 2 blood group antigen (Brown et al.,
1983). 365 antibody recognises an epitope expressed on CEA
but does not cross react with NCA.
Antibodies to normal components F15-42 reactive with
human Thy 1 (McKenzie & Fabre, 1981) and F10-89-4
(Dalchau et al., 1980) reactive with human leucocyte
common antigen were obtained from Serotec Ltd. (Bicester,
UK). These antibodies recognise stromal cells and leucocytes
respectively.
Cam 5.2 which recognises cytokeratin was purchased from
Becton Dickinson, Mountain View, CA.
Indirect immunofluorescence
Fresh or paraformaldehyde (1%, 5min) fixed cells were
stained by indirect immunofluorescence and analysed on a
FACS IV (Durrant et al., 1986a). Fluorescein fluorescence
was excited at 488nm and collected via a 10nm band pass
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filter centred at 515 nm and adjusted to standard conditions
using fluorochrome labelled latex beads. Fluorescence
intensity is expressed as mean linear fluorescence (MLF),
calculated by multiplying the contents of each channel by its
channel number and dividing by the total number of cells in
the distribution (Roe et al., 1985). The FACS IV is set to
selectively analyse cells in the malignant cell size range. Each
tumour or cell line was also stained using normal mouse Ig
and the MLF in this control was subtracted from the values
obtained with monoclonal antibody. However the mean
binding of normal mouse Ig was 50+25 and therefore
tumours were only described as positively staining if the
MLF exceeds 50+2s.d. i.e. 100. This was a conservative
estimate as background levels have already been subtracted.
The percentage of positively stained cells was calculated as
the number of cells with a fluorescence that exceeded the
value in which 95% of cells staining with normal mouse
immunoglobulin were observed.
DNA analysis
DNA was stained with mithramycin as previously described
(Durrant et al., 1986a). The DNA index was calculated as
the ratio of the mean relative DNA content of the G0/GI
cells of the sample divided by the mean of the relative DNA
measurement of the diploid GO/GI reference cells. Cells with
a normal diploid karyotype have by definition a DNA index
of 1.0. Tumour cells were defined as having an aneuploid
DNA content if their DNA index was between 1.1-1.9 and
greater than 10% of the total cells produced the abnormal
GO/G1 peak or if the index was between 1.9-2.1 if greater
than 15% of the total cells produced the second peak. If this
peak comprised less than 15% of the total cell population it
is assumed to be the G2 peak of diploid cells.
Clinicopathology
All tumour were staged according to Dukes' staging (Dukes,
1932) plus Stage D for distant metastases, and histologically
graded as well, moderately or poorly differentiated by
standard criteria.
Cell culture materials
The basal medium consisted of Dulbecco's minimal essential
medium (DMEM) supplemented with 10% heat inactivated
foetal calf serum (Gibco, Paisley).
Primary culture andpassage
Isolation and culture of C170, C146 and C168 cells has
previously been described (Durrant et al., 1986b). Cell lines
223, 224 and 225 were isolated and cultured by similar
procedures. Cell lines 277 and 280 were isolated from fresh
tumours as previously described (Durrant et al., 1986a) but
105 cells were plated into primaria plates (Falcon, Becton
Dickinson, Oxnard, CA) in DMEM supplemented with 20%
heat inactivated foetal calf serum, insulin (Sigma, Poole,
Dorset) gentamycin (Nicholas Labs. Ltd., Slough), pyruvate
(Flow Labs, Irving, Fife), non essential amino acids (Flow
Labs, Irving, Fife), oxaloacetic acid (Flow Labs. Irving, Fife)
and gastrin (Sigma, Dorset). When they formed confluent
monolayers they were removed by gentle pipetting and
transferred to flasks (Falcon, Becton Dickinson, Oxnard,
CA, USA). Cells in bulk culture were routinely passaged
twice weekly by detachment with gentle pipetting and re-
seeding 106 in 25cm3 or 75cm3 flasks.
Modulation of antigen expression was studied following
exposure of actively dividing cells to human recombinant y-
IFN (kindly provided by Boehringer, Ingelheim, Vienna,
Austria) at varying doses for 7 days.
Immunoperoxidase staining oftumour sections
Sections (5gim) of cryopreserved tumours or adjacent normal
large bowel tumours were stained by immunoperoxidase as
previously described (Holmes et al., 1984).
Results
Disaggregation ofsolid tumours
Disaggregation of solid tumours yields a mixed population
of cells including red blood cells, lymphocytes, stromal cells,
macrophages and endothelial cells. The percentage of
epithelial cells, as measured by staining of cytokeratin with
monoclonal antibody Cam 5.2, was only 22+13% (range
10-60). However following forward angle light scatter gating
to selectively analyse cells in the malignant cell size range
79+4% (range 69-86) of the cells analysed were epithelial.
Furthermore the variation between tumours was con-
siderably reduced.
The percentage of lymphocytes, as measued by staining
with the monoclonal antibody F10-89-4, in the total nucleate
population was 74+16 (range 40-90). This was considerably
reduced to 5.5+5% (range 1-20) following FACS IV gating
for malignant cell size. The percentage of stromal cells in the
population of cells analysed in the malignant size range was
3.5+3% (range 1-13).
Although the percentage of non epithelial cells in the
forward light scatter gate was low and did not vary consider-
ably between tumours (21 +4%). These cells may have
stained strongly with the monoclonal antibodies recognising
HLA-ABC or HLA-DR. This may have affected the mean
linear fluorescence of particular tumours or if they failed to
stain contributed to the heterogeneity of staining. Therefore
only tumour in which >25% (i.e. 21+4% non epithelial
cells) of the cells stained were described as positive and only
populations in which 25-75% of the cells stained were
described as heterogeneous. It was unlikely that the non
epithelial cells altered the intensity of binding of monoclonal
antibodies recognising either HLA-ABC or HLA-DR as no
distinct highly stained population of cells could be detected
on careful examination of the FACS IV fluorescence profiles.
Expression ofMHC antigens in relation to clinicopathological
stage and histological grade
Freshly isolated colorectal tumour cells bound monoclonal
antibody W6/32 with varying intensities (range of MLF of
0-3,110; Table I). This variation was not altered if the
tumour was disaggregated freshly or following an overnight
incubation in DMEM containing 20% foetal calf serum. The
range of MLFs corresponds to 0-1.5 x 106 HLA-ABC
antigens per cell. This assumes that an average of 2
molecules of anti mouse antibody bind to each monoclonal
antibody molecule. The fluorescence to protein ratio of the
anti mouse conjugate was 2.3 and under the analysis con-
ditions used there are approximately 2,200 fluorescein
isothiocyanate molecules per channel (Roe et al., 1985). The
majority of tumours (47%) stained in the range of MLFs of
500-1,000. Twenty four percent stained with a MLF
> 1,000, 19% stained with an MLF < 500 and 10% failed to
stain (MLF < 100). Two of the negative tumours stained
with monoclonal antibody W6/32 following fixation. There
was no obvious correlation with intensity of staining and
either clinicopathological stage or histological grade,
although the four negative tumours were from clinicopatho-
logical stages A, B and D whereas all the Dukes' C tumours
stained with an MLF in excess of 700.
RF-B-HLA-DR monoclonal antibody reacted with colo-
rectal tumours with a lower intensity (range of MLF 0-820;
Table II). than W6/32 monoclonal antibody. The range of
MLFs corresponds to 0-4.1 x 105 HLA-DR antigens per cell.QUANTITATION OF MHC ANTIGENS ON COLORECTAL TUMOURS 427
Table I Expression of HLA-ABC as recognised by W6/32
monoclonal antibody by immunofluorescence on disaggregated cells
from colorectal tumours
Immunofluorescence of W6/32 Clinicopathology
Tumour MLF % ofcells stained Differentiationb Stage
302 3,110 98 W A
301 2,327 99 W C
294 1,590 97 P B
296 1,586 96 M A
238 1,574 92 P C
299 1,558 98 M C
264 1,546 92 M B
125 1,381 76 M D
262 1,225 91 M A
142 1,978 92 M B
250 996 92 W C
248 958 62 P C
240 938 74 M D
290 849 86 M D
282 812 92 villous adenoma
279 809 52 P B
317 789 76 M B
298 777 88 M D
249 730 75 P A
275 720 62 P D
312 713 61 M B
281 700 84 M C
316 688 87 M B
318 670 83 P B
323 648 38 M B
283 569 83 M D
295 564 95 P B
314 545 68 villous adenoma
266 514 87 M D
310 506 76 P D
315 479 75 M B
241 453 66 M A
303 346 NDC M D
277 293 50 M A
242 241 56 M D
309 191 75 M B
236 188 80 M B
287 141 30 villous adenoma
278 37 5 W B
130 17 7 M D
265 0 (651)' 0 (43) M A
263 0 (809) 1 (52) M A
aFigures in parenthesis refer to MLF obtained on fixed cells; b W
well differentiated. M - moderately differentiated. P - poorly
differentiated; CND=not determined.
Only three (12%) of the tumours stained with RF-B-HLA-
DR in the range of MLF of 500-1,000, 12 (46%) tumours
stained below a MLF of 500 and 11 (42%) failed to stain
(MLF <100). Although all of the poorly differentiated
tumours expressed HLA-DR there was no correlation
between the intensity of staining and tumour differentiation.
There was no correlation with expression of HLA-DR and
clinicopathological stage.
Twenty-four percent of colorectal tumours stained hetero-
geneously with monoclonal antibody W6/32 (25-74% of
cells/tumour stained). Thirty-three percent of these were
poorly differentiated tumours whereas only 24% of the
tumours, where greater than 75% of the cells/tumour
stained, were poorly differentiated. None of the four well
differentiated tumours stained heterogeneously although only
68% and 30% of the cells of two of the three villous
adenomas stained with W6/32.
Fifty percent of the tumours stained with monoclonal
antibody RF-B-HLA-DR. Eighty-five percent of these
tumours stained heterogeneously and were either well,
Table II Expression of HLA-DR as recognised by RF-B-HLA-DR
monoclonal antibody by immunofluorescence on disaggregated cells
from colorectal tumours
Immunofluorescence ofRF-B-HLA-DR Clinicopathology
Tumour MLF % ofcells stained Differentiationa Stage
125 820 69 M D
299 667 94 M C
279 510 37 P B
295 454 83 P B
302 353 63 W A
290 253 52 M D
298 230 70 M D
294 222 51 P B
316 204 29 M B
275 180 28 P D
296 177 26 M A
301 176 32 W C
318 163 35 P B
323 145 15 M B
317 109 18 M B
310 88 15 M D
283 85 22 M D
315 60 11 M B
314 55 9 villous adenoma
312 55 6 M B
281 45 6 M C
303 45 NDb M D
278 35 7 W B
277 33 6 M A
282 26 8 villous adenoma
287 0 0 villous adenoma
aw well differentiated. M - moderately differentiated. P -
differentiated; bND =not determined.
poorly
Table III Expression of HLA-ABC and HLA-DR antigens as
recognised by W6/32 and RF-B-HLA-DR monoclonal antibody by
immunofluorescence staining of disaggregated cells from primary
and secondary colorectal tumours from the same patient
Immunofluorescence of W6/32 on:
Primary tumours Secondary tumours
Tumours MLF % ofcells stained MLF % ofcells stained
238 1,574 92 1,060a 53
299 1,558 98 2,913a 99
240 938 74 653 63
275 720 62 736 70
310 506 76 1,420 89
303 346 NDb 66 ND
242 241 56 2,248a 94
242 241 56 216 68
130 17 7 33 14
Immunofluorescence ofRF-B-HLA-DR on:
Primary tumours Secondary tumours
Tumours MLF % ofcells stained MLF % ofcells stained
299 667 94 1,070a 96
275 180 28 149 20
310 88 15 235 39
303 45 ND 13 ND
aSecondary tumour cells isolated from large hardened draining
lymph nodes. All other tumour cells were isolated from liver
metastases; bND=not determined.428 L.G. DURRANT et al.
moderately or poorly differentiated and from all clinico-
pathological stages.
Secondary tumours were obtained from nine patients.
Table III shows the intensity and percentage of cells staining
with W6/32 and RF-B-HLA-DR for each secondary and its
autologous primary tumour. There was no clear relationship
between the primary and autologous secondary tumours with
respect to either the intensity of cell surface staining or the
percentage of cells recognised.
Expression ofHLA-ABC and HLA-DR on cryopreserved
tumour sections
Tumours staining with varying intensities by immunofluor-
escence (MLF 293-1574) on disaggregated tumour cells were
also immunoperoxidase stained as cryopreserved tumour
sections (Table IV). The variation in intensity of staining of
W6/32 monoclonal antibody by immunofluorescence and
FACS IV analysis was not observed in the immunoperoxi-
dase stained sections. Six of the ten tumours stained strongly
immunohistochemically whilst the remaining four stained
moderately. Sections from two tumours stained with W6/32
immunohistochemically but failed to stain by immunofluor-
escence on fresh cells. However, when the cells from one of
these tumours was fixed, strong intracellular immunofluor-
escence staining was observed. Staining with the RF-B-HLA-
DR monoclonal antibody correlated for the two types of
staining. Tumour sections staining moderately, stained
moderately by immunofluorescence on fresh cells (MLFs
820-454) whereas tumours staining weakly by immuno-
peroxidase staining of tumour sections stained weakly by
immunofluorescence (MLF 33-225). However the variation
in intensities between individual tumours was much clearer
by FACS IV analysis of freshly stained cells.
Immunohistochemical staining of normal large bowel
showed uniform staining with W6/32 monoclonal antibody
and no HLA-DR staining (data not shown).
Table IV Expression of HLA-ABC or HLA-DR as recognised by
W6/32 and RF-B-HLA-DR on cryopreserved tumour sections or on
disaggregated tumour cells
Staining with W6/32
Immunochemistry Immunofluorescence (MLF)
Tumour (cryopreserved sections) (fresh tumour cells)
238 2 +a 1,574
264 2+ 1,546
125 2+ 1,381
250 + 996
249 + 730
283 2+ 569
266 2+ 514
277 + 293
263 + 0
265 2+ 0 (651)
Staining with RF-B-HLA-DR
Immunochemistry Immunofluorescence (MLF)
Tumour (cryopreserved sections) (fresh tumour cells)
125 + 820
299 + 667
279 + 510
295 + 454
298 + 225
283 + 85
277 + 33
a2+ strong, +moderate, +weak.
Table V Expression of MHC and tumour associated antigens in
newly derived colorectal tumour cell lines
Immunofluorescence with monoclonal antibodies (MLF):
Culture W6/32 RF-B-HLA-DR C14 791T/36
C146 0 (320) 7 (155) 3,242 377
C168 11 (538) 108 (1,036) 2,195 184
C170 5 (42) 7 (155) 2,298 185
223 0 (354) 0 (156) 1,274 532
224 0 (554) 0 (920) 549 478
225 0 (351) 31 (750) 479 138
277 378 (524) 10 (10) 278 798
280 408 (525) 9 (56) 765 300
Figures in parenthesis refer to MLF values obtained following
paraformaldehyde fixation.
Expression ofMHC antigens on colorectal cells growing in
early in vitro culture
In contrast to the primary tumours, where 90% stained with
monoclonal antibody W6/32, only two of the eight tumours
which grew in vitro expressed HLA-ABC antigens at their
cell surface. However, seven out of eight of these cultures
expressed internal HLA-ABC antigens which were detected
in fixed but not fresh cells (Table V). Only one of the cell
lines expressed HLA-DR on its membrane whereas 50% of
the primary tumours reacted with the RF-B-HLA-DR
monoclonal antibody. However, 75% of these cultures
expressed internal HLA-DR antigen which could be detected
by RF-B-HLA-DR in fixed cells. (Table V). Furthermore
two of the cell lines, C170 and C168 could be induced to
express HLA-DR at their cell surface (Figure 1).
All of the early in vitro cultures expressed the tumour
associated antigens defined by the monoclonal antibodies
C14 and 791T/36 (Table V).
a)
a)
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Figure 1 Expression ofHLA-ABC and HLA-DR as recognised by
monoclonal antibodies W6/32 and RF-B-HLA-DR in C170 cells in
thepresenceofhumanrecombinantylFN.(@)C170cellsstainedwith
RF-B-HLA-DR, (0) C170 cells stained with W6/32, (-) C168 cells
stained with RF-B-HLA-DR, (Cl) C168 cells stained with W6/32.QUANTITATION OF MHC ANTIGENS ON COLORECTAL TUMOURS 429
Table VI Expression of HLA-ABC and HLA-DR antigens as recognised by W6/32 and
RF-B-HLA-DR monoclonal antibodies in an immunofluorescence assay on collagenase dis-
aggregated cells from a series of adenocarcinomas
Immunofluorescence
Aneuploid Diploid
W6/32 RF-B-HLA-DR W6/32 RF-B-HLA-DR
MLF % positive MLF % positive MLF % positive MLF % positive
1,574 92 NDa ND 730 75 ND ND
938 74 ND ND 996 92 ND ND
241 56 ND ND 706 62 ND ND
700 84 45 5 1,546 92 ND ND
569 83 85 20 0 0 0 0
1,590 97 222 51 720 62 180 28
564 95 454 83 293 50 33 6
1,558 98 667 94 812 92 126 8
2,327 99 176 32 1,585 96 177 8
3,110 98 353 63 153 27 353 63
506 76 88 15 191 75 88 15
479 75 60 10 713 61 60 10
688 87 204 29 545 68 55 6
aND =not determined.
Table VII Expression of MHC and tumour associated antigens in colorectal cancer
% oftumours co-expressing MHC antigens and tumour associated antigens
Tumours co-staining Immunofluorescence with W6/32:
by immunofluorescence
with thefollowing 100-75% ofcellsl 74-25% ofcellsl <25% ofcells/
monoclonal antibodies tumour stained tumour stained tumour stained
C14, 365, 791T/36 73 50 0
C14, 365 16 12.5 0
C14, 791T/36 0 12.5 0
C14 11 25 33
365 0 0 67
Tumours co-staining Immunofluorescence with RF.B:HLA-DR:
by immunofluorescence
with thefollowing 10f-75% ofcells! 74-25% ofcells! <25% ofcells/
monoclonal antibodies tumour stained tumour stained tumour stained
C14, 365, 791T/36 100 75 52
C14, 365 0 12.5 16
C14 0 12.5 16
365 0 0 16
Expression ofMHC antigens in relation to DNA ploidy
The aneuploid tumours bound W6/32 and RF-B-HLA-DR
monoclonal antibodies with significantly stronger intensities
(t=2.4; P<0.05; t=2.5; P<0.05) than diploid tumours
(Table VI). Only one of the aneuploid tumours stained
heterogeneously whereas over half of the diploid tumours
showed this patchy expression. Eighty percent of the
aneuploid tumours expressed HLA-DR whereas only 27% of
diploid tumours expressed this antigen.
Expression ofHLA-ABC and HLA-DR antigens in relation to
tumour associated antigens
Seventy-three percent of the tumours, in which >75% of the
cells expressed HLA-ABC, also expressed the epitopes
defined by monoclonal antibodies C14, 365 and 791T/36
(Table VII). Only 50% of the tumours staining hetero-
geneously, and none of the tumours failing to stain with
monoclonal antibody W6/32, co-expressed the three tumour
associated antigens. One hundred percent of the tumours
which failed to express HLA-ABC only co-expressed one
tumour associated antigen. HLA-ABC was never expressed
on its own (Table VII).
There was no correlation between the intensity of staining
with W6/32 monoclonal antibody and the monoclonal anti-
bodies RF-B-HLA-DR, C14, 365 and 791T/36 (Table VIII).
All of the tumours in which >75% of the cells stained
with RF-B-HLA-DR co-expressed the epitopes defined by
monoclonal antibodies C14, 365 and 791T/36. Seventy-five
percent of tumours staining heterogeneously with mono-
clonal antibody RF-B-HLA-DR and 52% of the tumours
which failed to stain, also stained with monoclonal anti-
bodies C14, 365 and 791T/36. Thirty-two percent of the
tumours which failed to express HLA-DR antigen only co-
expressed one of the tumour associated antigens. HLA-DR
antigen was never expressed on its own.430 L.G. DURRANT et al.
Table VIII Expression of HLA-ABC and HLA-DR antigens in
association with carcinoembryonic antigen, 791T p72 and Y hapten
blood group as recognised by the monoclonal antibodies W6/32,
RF-B-HLA-DR, C14, 365, 791T/36
Immunofluorescence staining with monoclonal antibodies
(MLF)
Tumour W6/32 RK
302 3,110
301 2,327
294 1,590
296 1,586
238 1,574
299 1,558
264 1,546
125 1,381
262 1,225
142 1,078
248 958
290 849
282 812
279 809
317 789
298 777
275 720
312 713
281 700
316 688
318 670
323 648
283 569
295 564
314 545
266 514
310 506
315 479
241 453
303 346
277 293
242 241
309 191
236 188
287 141
278 37
265 0
263 0
aND: not determined
'F-B-HLA-DR
353
176
222
177
NDa
667
ND
820
ND
ND
ND
253
26
510
109
230
180
55
45
204
163
145
85
454
55
ND
88
60
ND
45
33
ND
55
ND
0
35
ND
ND
C14
1,778
793
525
515
406
1,744
1,453
1,430
671
1,179
1,158
280
159
1,122
563
927
ND
404
166
466
1,516
1,909
1,397
126
107
571
470
312
217
145
73
548
177
1,661
240
20
214
114
365
225
1,276
1,638
1,025
832
1,471
1,042
506
936
866
50
350
61
65
281
1,414
1,912
272
400
317
1,529
764
1,740
247
200
677
847
403
618
158
148
2,121
77
2,020
51
478
27
0
791T/36
25
300
586
466
655
1,278
133
366
40
463
162
240
17
83
104
324
237
111
157
140
609
323
123
152
43
S
319
85
566
194
21
200
71
1,423
28
52
16
0
Discussion
The majority of nucleated cells express HLA-ABC antigens
(Bodmer, 1981). Thirty-four percent of the colorectal
tumours when analysed by a FACS IV cells sorter were
partially or completely negative for cell surface HLA-ABC
antigen expression. This agreed with the results of Csiba et
al. (1984) who observed partial absence of class I antigens in
40% of their colorectal cancers. However, Momburg et al.
(1986) only observed loss of HLA-ABC antigens in 13% of
colorectal cancers analysed and Daar and Fabre (1983)
observed loss of class I in only 1/15 of the colorectal cancers
they studied. Tumours stained by immunohistochemistry are
fixed prior to staining and therefore it is impossible to
distinguish internal and external antigen expression. Interest-
ingly two of the tumours which failed to express HLA/ABC
could be stained with W6/32 monoclonal antibody following
fixation. Similarly 6 of the 8 cultured cell lines only
expressed internal HLA-ABC antigens. Negative results
reflect abnormalities in the synthesis, assembly, insertion into
the plasma membrane and for shedding of HLA-ABC
antigens. Expression of only internal antigen in some
primary tumours and cultured cell lines maybe suggests an
abnormality in insertion into the plasma membrane.
Biological behaviour, as measured by tumour growth and
propensity to metastasise varies considerably between
tumours of a given type. As the external membrane of
tumours and all other cells dictates the nature of their
interactions with their environment, membrane changes may
be associated with tumour behaviour. This study was con-
cerned with quantitative evaluation of cell surface MHC
(and tumour associated antigen expression) as a potential
marker of tumour progression.
There was an enormous variation in the intensity of
staining with W6/32 monoclonal antibody which could not
be detected by immunohistochemistry. The level of class I
antigen expression may affect sensitivity to lysis by natural
killer cells (Ljunggren & Karre, 1985). Studies with rat
tumour cells indicated that the appearance of increased class
I antigen induced by rat yIFN closely parallels changes in
sensitivity to natural killer cells (Yeoman et al., 1986).
Although there was no correlation between the intensity of
staining with W6/32 monoclonal antibodies and either histo-
logical grade or clinicopathological stage A, it will be
interesting to see if there is any subsequent correlation with
patient survival. In the mouse TIO sarcoma model manipu-
lations which resulted in increased class I antigen expression
were associated with increased metastatic potential (Katzav
et al., 1983). This was related to high levels of H-2D
expression whereas gene transfection studies in the same lines
showed that increased H-2K gene expression resulted in
variants with decreased metastatic activity. Furthermore, this
effect was related to an immune response, as the same
variants metastasized in immunodeprived recipients (Wallich
et al., 1985). These findings are consistent with the
hypothesis that tumour associated antigens are recognised in
the context of H-2K and not H-2D class I antigens. Further
studies using monoclonal antibodies specific to each of the
human class I loci will determine if any one MHC class
locus is a better indicator of tumour aggression.
Epithelial cells do not usually express HLA-DR antigens
however 50% of the colorectal tumours expressed this
antigen. Although the intensity of staining varied
enormously (range of MLFs of 0-810), the majority of
tumours stained weakly (MLF <300). All of the poorly
differentiated tumours expressed HLA-DR confirming the
suggestion of Rognum et al. (1983) that HLA-DR expression
is more consistent in poorly differentiated tumours. In
agreement with previous studies (Daar & Fabre, 1983; Csiba
et al., 1984) there was no correlation between expression of
HLA-DR antigen and clinicopathological stage. Expression
of HLA-DR antigens on primary tumours can augment the
immunogenicity of tumour associated antigens as they are
important in antigen presentation to helper T-lymphocytes
(Fossati et al., 1984). However, metastatic melanoma cells
expressing high levels of HLA-DR antigens can inhibit the
immune response of autologous peripheral blood lympho-
cytes. Furthermore it appears that a T-lymphocyte-derived
lymphokine such as yIFN can influence both the phenotype
and the suppressive activity of autologous metastatic
melanoma cells (Taramelli et al., 1984).
Although Thompson et al. (1982) reported that metastatic
colorectal tumours were consistently HLA-DR antigen
negative, 2/4 of our secondary tumours expressed this
antigen. However, it was found that the majority of early
derived in vitro dividing cells were consistently negative for
both HLA-ABC and HLA-DR antigens. However, re-
expression of MHC antigens could be induced in several cell
lines by the immune regulator yIFN. This could imply that
antigen expression in vivo is induced by local yIFN, and the
lack of expression in vitro is due to lack of yIFN. Alter-
natively if there is a correlation between in vitro and in vivo
growth perhaps tumours are maintained and seed by cell
surface MHC antigen negative cells which may escape
immune recognition. Re-expression on maturation may be
controlled by immune regulators such as yIFN.
In agreement with Rognum et al. (1982) the aneuploid
tumours stained more homogeneously with RF-B-HLA-DRQUANTITATION OF MHC ANTIGENS ON COLORECTAL TUMOURS 431
and with a higher intensity than the diploid tumours. This
study also showed a similar correlation with expression of
HLA-ABC antigens. Abnormal expression of the tumour
associated antigens CEA, Y haptenic blood group and 791T
p72 also correlated with expression of HLA-ABC and HLA-
DR antigens on colorectal tumours. Previous studies show
that tumour associated antigens are also expressed more
strongly on aneuploid than diploid tumours (Durrant et al.,
1986a). Perhaps gene amplification in aneuploid tumours
results in increased antigen expression. Our group has
previously shown that patients with aneuploid tumours have
a significantly worse survival than patients with diploid
tumours (Armitage et al., 1985). Perhaps elevated HLA-class
I expression is associated with increased metastatic potential
as seen in animal models (Katzav et al., 1983).
Prospective studies currently in progress should determine
if the quantity of MHC antigens on human colorectal cancer
correlates with tumour recurrence, and metastatic spread,
allowing an early prediction of which stage B and C tumours
are most aggressive.
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